David A. Siegel Novavax Inc Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Novavax Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 21,700 shares of NVAX stock, worth $184,016. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,700
Previous 614,000
96.47%
Holding current value
$184,016
Previous $3.94 Million
96.54%
% of portfolio
0.0%
Previous 0.01%
Shares
18 transactions
Others Institutions Holding NVAX
# of Institutions
317Shares Held
94.6MCall Options Held
6.38MPut Options Held
10.6M-
Vanguard Group Inc Valley Forge, PA15.4MShares$131 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.8MShares$100 Million0.0% of portfolio
-
Shah Capital Management11.5MShares$97.6 Million35.13% of portfolio
-
State Street Corp Boston, MA6.82MShares$57.9 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.94MShares$33.4 Million0.02% of portfolio
About NOVAVAX INC
- Ticker NVAX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,215,104
- Market Cap $663M
- Description
- Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...